Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

LAVAL, QC, Jan. 14 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude enrolment next month for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel(R). To date, the Company has enrolled more than 70 subjects and participating clinical sites will be permitted to enrol additional subjects until February 10th, 2009.

"With the certainty provided by this date, we are now sure that the final results from this pivotal trial will be available in the first quarter of 2010, once the last treated subject has completed their twelve-month follow up period. Furthermore, we are confident that the current number of enrolled subjects already represents a sufficiently powered study and that with this data we can meet the overall objectives of the study," said Michel Lagueux, Chairman of the Board of Directors. "At the same time, we remain sensitive to the fact that there are eligible individuals who still want a chance to participate in the study and we will work closely with our investigators over the next four weeks to ensure that as many as possible can be enrolled."

"I am very proud to be involved in the clinical development of this important new therapy in what is the largest randomized clinical trial for cartilage repair ever conducted in North America. Enrolment was certainly the greatest challenge, given our adherence to strict subject eligibility criteria, but in the end this rigour will ensure trial data of the highest quality and integrity," said Dr. William Stanish, Professor of Surgery at Dalhousie University in Halifax, Nova Scotia, and Principal Investigator for the trial.

Mr. Lagueux continued, "BioSyntech would like to acknowledge the team of over 25 orthopaedic surgeons and their support staff for their sincere dedication and perseverance in achieving this enrolment milest
'/>"/>

SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... TORONTO, Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: ... key terms with Toray,Industries Inc. of Japan to ... U.S. for Toraymyxin(TM), a therapeutic for the treatment ... the terms of the,agreement, the Company will seek ...
... InspireMD, Ltd.,announced today the enrollment of the first ... in acute myocardial infarction. The GUARD Study,(MGuard(TM) in ... safety and efficacy of MGuard(TM) in patients suffering ... were implanted,successfully with the MGuard(TM) Coronary Stent, in ...
... on Nano-Bio-Info-Cogno (NBIC) technologies and their interactions will ... Museum in Mountain View, California. The event ... participants to customize the event in a highly ... forecaster with over two decades experience exploring long-term ...
Cached Biology Technology:Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 2Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 3
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... announced today its involvement in an expanded access ... treatment for phenylketonuria (PKU), a rare genetic metabolic ... children, can result in severe mental retardation. Currently, ... access program at Nationwide Childrens. Under an ...
... Society and other institutions declare that improvements in ... double the number of tigers currently existing in the ... in the most recent edition of the journal Biological ... the Indian subcontinentcomprising India, Bangladesh, Bhutan, and Nepal. It ...
... Boulder, CO, USA - Topics include: continental deformation ... Mars; correlation of 200-million-year-old rocks between Britain and ... mass extinctions; rock weathering in Canada,s Mackenzie River ... how stable continents split in the absence of ...
Cached Biology News:Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2November GEOLOGY and GSA TODAY Media Highlights 2November GEOLOGY and GSA TODAY Media Highlights 3November GEOLOGY and GSA TODAY Media Highlights 4November GEOLOGY and GSA TODAY Media Highlights 5November GEOLOGY and GSA TODAY Media Highlights 6November GEOLOGY and GSA TODAY Media Highlights 7November GEOLOGY and GSA TODAY Media Highlights 8November GEOLOGY and GSA TODAY Media Highlights 9November GEOLOGY and GSA TODAY Media Highlights 10
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Second Mitochondria Derived Activator of Caspase/DIABLO ... HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. Amino acid ... a carboxy terminal His•Tag ® sequence was ... . Smac/DIABLO is released along with cytochrome ...
... polyclonal to Decorin ( Abpromise ... Antigen: Synthetic peptide: IGPEVPDDRDFEPS ... acids 6-19 of Human Decorin (fragment ... proteoglycan II). Entrez ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
Biology Products: